143 related articles for article (PubMed ID: 20089548)
1. Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.
Höybye C; Ragnarsson O; Jönsson PJ; Koltowska-Häggström M; Trainer P; Feldt-Rasmussen U; Biller BM
Eur J Endocrinol; 2010 Apr; 162(4):677-84. PubMed ID: 20089548
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density.
Colson A; Brooke AM; Walker D; Besser GM; Chew SL; Grossman AB; Jenkins PJ; Drake WM; Monson JP
Horm Res; 2006; 66(6):257-67. PubMed ID: 16914933
[TBL] [Abstract][Full Text] [Related]
3. Baseline characteristics and response to 2 years of growth hormone (GH) replacement of hypopituitary patients with GH deficiency due to adult-onset craniopharyngioma in comparison with patients with nonfunctioning pituitary adenoma: data from KIMS (Pfizer International Metabolic Database).
Verhelst J; Kendall-Taylor P; Erfurth EM; Price DA; Geffner M; Koltowska-Häggström M; Jönsson PJ; Wilton P; Abs R
J Clin Endocrinol Metab; 2005 Aug; 90(8):4636-43. PubMed ID: 15928246
[TBL] [Abstract][Full Text] [Related]
4. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
[TBL] [Abstract][Full Text] [Related]
5. Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood.
Ragnarsson O; Höybye C; Jönsson PJ; Feldt-Rasmussen U; Johannsson G; Biller BM; Koltowska-Häggström M
Eur J Endocrinol; 2012 Apr; 166(4):593-600. PubMed ID: 22258111
[TBL] [Abstract][Full Text] [Related]
6. Sheehan's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database.
Kelestimur F; Jonsson P; Molvalilar S; Gomez JM; Auernhammer CJ; Colak R; Koltowska-Häggström M; Goth MI
Eur J Endocrinol; 2005 Apr; 152(4):581-7. PubMed ID: 15817914
[TBL] [Abstract][Full Text] [Related]
7. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.
Webb SM; Mo D; Lamberts SW; Melmed S; Cavagnini F; Pecori Giraldi F; Strasburger CJ; Zimmermann AG; Woodmansee WW;
J Clin Endocrinol Metab; 2010 Feb; 95(2):630-8. PubMed ID: 20022992
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
[TBL] [Abstract][Full Text] [Related]
9. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database.
Abs R; Mattsson AF; Bengtsson BA; Feldt-Rasmussen U; Góth MI; Koltowska-Häggström M; Monson JP; Verhelst J; Wilton P;
Growth Horm IGF Res; 2005 Oct; 15(5):349-59. PubMed ID: 16168692
[TBL] [Abstract][Full Text] [Related]
10. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board.
Bengtsson BA; Abs R; Bennmarker H; Monson JP; Feldt-Rasmussen U; Hernberg-Stahl E; Westberg B; Wilton P; Wüster C
J Clin Endocrinol Metab; 1999 Nov; 84(11):3929-35. PubMed ID: 10566630
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and effects of GH replacement therapy in adults with childhood-onset craniopharyngioma compared with those in adults with other causes of childhood-onset hypothalamic-pituitary dysfunction.
Yuen KC; Koltowska-Häggström M; Cook DM; Fox JL; Jönsson PJ; Geffner ME; Abs R
Eur J Endocrinol; 2013 Oct; 169(4):511-9. PubMed ID: 23904277
[TBL] [Abstract][Full Text] [Related]
12. GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database.
Gardner CJ; Mattsson AF; Daousi C; Korbonits M; Koltowska-Haggstrom M; Cuthbertson DJ
Eur J Endocrinol; 2015 Apr; 172(4):371-81. PubMed ID: 25583905
[TBL] [Abstract][Full Text] [Related]
13. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
14. Growth hormone (GH) deficiency and GH replacement therapy in patients previously treated for Cushing's disease.
Boguszewski CL
Pituitary; 2022 Oct; 25(5):760-763. PubMed ID: 35552989
[TBL] [Abstract][Full Text] [Related]
15. Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: A KIMS-based study.
Casanueva FF; Leal A; Koltowska-Häggström M; Jonsson P; Góth MI
Arch Phys Med Rehabil; 2005 Mar; 86(3):463-8. PubMed ID: 15759229
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease.
Feldt-Rasmussen U; Abs R; Bengtsson BA; Bennmarker H; Bramnert M; Hernberg-Ståhl E; Monson JP; Westberg B; Wilton P; Wüster C;
Eur J Endocrinol; 2002 Jan; 146(1):67-74. PubMed ID: 11751070
[TBL] [Abstract][Full Text] [Related]
17. Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease.
Johannsson G; Sunnerhagen KS; Svensson J
Clin Endocrinol (Oxf); 2004 May; 60(5):550-9. PubMed ID: 15104557
[TBL] [Abstract][Full Text] [Related]
18. Influences on quality of life in GH deficient adults and their effect on response to treatment.
Murray RD; Skillicorn CJ; Howell SJ; Lissett CA; Rahim A; Smethurst LE; Shalet SM
Clin Endocrinol (Oxf); 1999 Nov; 51(5):565-73. PubMed ID: 10594517
[TBL] [Abstract][Full Text] [Related]
19. The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy.
Mukherjee A; Tolhurst-Cleaver S; Ryder WD; Smethurst L; Shalet SM
J Clin Endocrinol Metab; 2005 Mar; 90(3):1542-9. PubMed ID: 15613427
[TBL] [Abstract][Full Text] [Related]
20. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
Feldt-Rasmussen U; Wilton P; Jonsson P; ;
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]